Compare Figs Inc (FIGS) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Invesco Ltd. — how do they compare? Figs Inc trades at $15.76 (market cap $2.49B), while Invesco Ltd. trades at $29.52 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 5.3× Figs Inc's market cap, and Invesco Ltd. pays a 2.86% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Invesco Ltd. for 77 Days on average.
| FIGS | IVZ | |
|---|---|---|
Market Cap | $2.49B | $13.28B |
Volume | 5,964,311 | 3,698,033 |
Sector | Consumer Cyclical | Financials |
52-Week High | $17.12 | $33.31 |
52-Week Low | $6.90 | $22.44 |
Typical Hold Time | 33 Days | 77 Days |
Enterprise Value | $2.25B | $23.45B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth from $556M in 2024 to $631M in 2025, with net income improving to $34M. Recent Q2 2026 earnings beat expectations by 64%, and international sales surged 67% according to Zacks Research on August 20, 2026. The stock faces valuation concerns with a P/E of 45.39, but analyst consensus targets $18.00 representing 14% upside potential.
Outlook remains positive with projected 2026 revenue of $710M and net income of $62M, though rich valuation requires continued execution. Key risks include competitive pressures and margin sustainability. With 60% analyst buy ratings and improving cash flow projections, FIGS offers growth exposure but demands careful risk management given premium multiples.
Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.
The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
